The vaccine primes T cells against patient-specific neoantigen peptides; cytotoxic T cells kill cells presenting those neoantigen peptides on HLA (mainly class I) via perforin/granzyme. HLA-DRA (MHC II) itself is not a target, so cells expressing HLA-DRA are not killed for expressing it.